Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACUS OTCMKTS:ALSE OTCMKTS:AOLS OTCMKTS:PVTTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACUSAcusphere$0.00$0.00▼$0.00N/A-1.87N/AN/AALSEAlseres Pharmaceuticals$0.01$0.01$0.01▼$0.01N/AN/AN/AN/AAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.31N/AN/APVTTFPivotal Therapeutics$0.00$0.00$0.00▼$0.00N/A-0.41N/AN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACUSAcusphere0.00%0.00%0.00%0.00%+900.00%ALSEAlseres Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PVTTFPivotal Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACUSAcusphereN/AN/AN/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APVTTFPivotal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACUSAcusphere 0.00N/AN/AN/AALSEAlseres Pharmaceuticals 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/APVTTFPivotal Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACUSAcusphereN/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/APVTTFPivotal TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACUSAcusphereN/AN/A0.00N/AN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/APVTTFPivotal TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACUSAcusphereN/AN/AN/AN/AN/AALSEAlseres PharmaceuticalsN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/APVTTFPivotal TherapeuticsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACUSAcusphereN/AALSEAlseres PharmaceuticalsN/AAOLSAeolus PharmaceuticalsN/APVTTFPivotal TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACUSAcusphere4.60%ALSEAlseres Pharmaceuticals8.94%AOLSAeolus Pharmaceuticals66.60%PVTTFPivotal TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACUSAcusphere118N/AN/ANot OptionableALSEAlseres Pharmaceuticals3N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionablePVTTFPivotal TherapeuticsN/AN/AN/ANot OptionablePVTTF, ACUS, AOLS, and ALSE HeadlinesRecent News About These CompaniesKrabbe Disease Treatment Market Size & Share 2033May 24, 2024 | pharmiweb.comPDermal Filler Market Expected to Reach USD 10.1 Billion by 2032, Growing at 9.4% CAGR | Marketresearch.biz ReportMay 24, 2024 | pharmiweb.comPFluidx Receives IDE Approval for Pivotal Trial of GPX Embolic DeviceMay 21, 2024 | evtoday.comEDrug Addiction Treatment Market Trends, Drivers, and Forecasts up to 2033 | Marketresearch.bizMay 21, 2024 | pharmiweb.comPAfrica a crucial partner to achieving Global Pivotal State — South KoreaMay 19, 2024 | msn.comWikiLeaks Founder Julian Assange Facing Pivotal Moment in Long Fight to Stay Out of US CourtMay 19, 2024 | msn.comZuma in Court Seeking Right to Run in South Africa's Pivotal ElectionMay 10, 2024 | usnews.comVTv Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | timesunion.comT'Lirafit's impact could alleviate the diabetes burden in India in terms of cost & quality of life'May 6, 2024 | health.economictimes.indiatimes.comKawhi Leonard Ruled Out for Clippers' Pivotal Game 5 Vs MavericksApril 30, 2024 | msn.comAntibody Production Market Will Grow Nearly USD 62.2 Billion At A Rate Of 12.9% By 2033April 29, 2024 | pharmiweb.comPPivotal Point executive director set to retireApril 27, 2024 | newspressnow.comNETPharma to host Biomolecule Workshop & Connect Mumbai Chapter 2024April 26, 2024 | health.economictimes.indiatimes.comGenotyping Market Forecast: USD 73.5 Billion by 2032, Growth at CAGR of 15.5%April 26, 2024 | pharmiweb.comPBiden Sees a $35 Price Cap for Insulin as a Pivotal Campaign Issue. It’s Not That Clear-CutApril 21, 2024 | usnews.comThe Latest | Jury Selection Enters a Pivotal Stretch as Trump's Hush Money Trial ResumesApril 18, 2024 | msn.comJury Selection in Trump Hush Money Trial Faces Pivotal Stretch as Former President Returns to CourtApril 17, 2024 | usnews.comAnti-Trump Republican Larry Hogan Navigates Dangerous Political Terrain in Pivotal Senate ContestApril 16, 2024 | usnews.comAmen Corner Proves Pivotal as Scottie Scheffler's Closest Pursuers Falter in Final Round of MastersApril 14, 2024 | msn.comBotulism Market Anticipated to Reach USD 13.5 Billion by 2032, CAGR 6.8% | Marketresearch.bizApril 12, 2024 | pharmiweb.comPPVTTF, ACUS, AOLS, and ALSE Company DescriptionsAcusphere OTCMKTS:ACUSAcusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.Alseres Pharmaceuticals OTCMKTS:ALSE$0.0050 0.00 (0.00%) As of 10/18/2024Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.Pivotal Therapeutics OTCMKTS:PVTTF$0.0018 0.00 (0.00%) As of 05/12/2023Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler's health, child's health, and pet's health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
